Notably, a real-world study on pancreatic neuroendocrine tumors (a shared neuroendocrine malignancy) demonstrated that PAK4 overexpression correlates with adverse prognosis, and pharmacological inhibition of PAK4 significantly suppresses tumor progression (Azar et al., 2025). Here, PAK4 is linked to pancreatic neuroendocrine tumor.